Acurx Pharmaceuticals, Inc.
General ticker "ACXP" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $10.7M (TTM average)
Acurx Pharmaceuticals, Inc. does not follow the US Stock Market performance with the rate: -15.2%.
Estimated limits based on current volatility of 5.1%: low 3.24$, high 3.59$
Factors to consider:
- Total employees count: 4 (+33.3%) as of 2022
- Top business risk factors: Going concern, Capital raising, Product reliance, Management dependency, Product liability
- Current price 57.5% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [8.19$, 27.90$]
- 2025-12-31 to 2026-12-31 estimated range: [5.12$, 17.15$]
Financial Metrics affecting the ACXP estimates:
- Negative: with PPE of -19.0 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -73.57 <= 0.33
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Negative: Shareholder equity ratio, % of 15.94 <= 18.93
- Negative: Industry earnings per price (median), % of -16.34 <= 0
- Positive: Inventory ratio change, % of 0 <= 0
Short-term ACXP quotes
Long-term ACXP plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $12.09MM | $14.58MM | $14.10MM |
| Operating Income | $-12.09MM | $-14.58MM | $-14.10MM |
| R&D Expense | $4.75MM | $6.04MM | $5.40MM |
| Income(Loss) | $-12.09MM | $-14.58MM | $-14.10MM |
| Profit(Loss)* | $-12.09MM | $-14.58MM | $-14.10MM |
| Stockholders Equity | $7.32MM | $4.67MM | $0.62MM |
| Assets | $9.38MM | $7.71MM | $3.86MM |
| Operating Cash Flow | $-7.54MM | $-9.80MM | $-10.38MM |
| Financing Cash Flow | $3.70MM | $8.16MM | $6.62MM |
| Earnings Per Share** | $-22.36 | $-23.01 | $-16.56 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.